Zepteon has developed a breakthrough antibody development and manufacturing technology that enables biopharmaceutical companies to evaluate and tune their drug potency. This is accomplished by separating high potency antibodies (nonfucosylated) from complex mixtures using our Glycap-3A chromatography resin. This technology streamlines the regulatory required structure:function characterization activities and enables a new method of drug manufacturing for biosimilars, biobetters and novel therapeutics.
In 2012 the global monoclonal antibody market exceeded $40 billion in sales and the antibody biosimilars market is projected to exceed $25 billion. In addition, there are at least ten currently licensed human plasma derived antibody therapeutics that together comprise more than $6 billion in annual US revenue. In exchange for fees, milestones and royalties on drug sales, our technology can enable more efficient development and manufacturing of drugs in these markets.